作者: Tamson V. Moore , Michael I. Nishimura
DOI: 10.1038/S41571-019-0315-0
关键词:
摘要: Numerous neoepitope-based vaccination strategies are in testing for clinical use the treatment of cancer. Rapid identification immunostimulatory neoantigen targets hastens vaccine development. Papers recently published Nature Biotechnology describe two independent machine-learning-based algorithms that demonstrate improved MHC class II-binding peptides. Herein, we outline benefits these and their implications future immunotherapies.